Japanese Encephalitis

News Japanese Encephalitis

• Zika vaccine induces strong immune response in three phase 1 studies
  

  Three Phase 1 human clinical trials evaluating an Army-developed Zika purified inactivated virus (ZPIV) vaccine have shown it was safe and well-tolerated in healthy adults and induced a robust immune response. Each of the three studies included in the paper was designed to address a unique question more

• Sanofi Pasteur signs research agreement for Zika Vaccine

  Sanofi and its vaccines global business unit Sanofi Pasteur announced today a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research (WRAIR) on the co-development of a Zika vaccine candidate.  According to the terms of the agreement, WRAIR will transfer its Zi more

• VABIOTECH licenses cell-based japanese encephalitis technology from Inviragen

  The Company for Vaccine and Biological Production No.1 (VABIOTECH) and Inviragen, Inc. announced a licensing agreement by which VABIOTECH will acquire rights to Inviragen’s proprietary Japanese encephalitis (JE) technology to produce a cell-derived vaccine. A cell-based JE vaccine has the potential more